Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus PGV001 in urothelial cancer
NCT03359239Phase 1Completed
- Start
- May 2019
- Primary completion
- Oct 2021
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PGV-001 in urothelial carcinoma (UC). Primary endpoints: Number of neoantigens identified up to 24 months, Number of peptides synthesized up to 24 months and 4 more. Started May 2019; status: completed.
02
Drugs
PGV-001
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03359239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03359239.